Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Douketis

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Current Opinion in Hematology|August 12, 2005
Hormone replacement therapy and risk for venous thromboembolism: what's new and how do these findings influence clinical practice?James Douketis
ACP Journal Club|May 3, 2002
Review: stress hyperglycemia after ischemic stroke indicates a greater risk for death in patients without diabetesJames Douketis
Annals of Internal Medicine|May 18, 2011
ACP journal club. Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacementJames Douketis
ACP Journal Club|March 5, 2003
Heparin plus alteplase reduced morbidity more than heparin alone in submassive pulmonary embolismJames Douketis
Annals of Internal Medicine|May 18, 2011
ACP journal club. Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatmentJames Douketis
ACP Journal Club|September 5, 2002
Review: postmenopausal estrogen replacement therapy increases the risk for venous thromboembolismJames Douketis
Annals of Internal Medicine|July 22, 2009
ACP Journal Club. The devil is in the details...or not? A primer on individual patient data meta-analysisSachin Sud, James Douketis
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|April 29, 2014
New oral anticoagulants and oculoplastic surgeryEdsel Ing, James Douketis
Expert Opinion on Pharmacotherapy|February 19, 2013
Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient managementAaron Liew, James Douketis
BMJ (Clinical Research Ed.)|September 11, 2013
Secondary prevention of venous thromboembolismSam Schulman, James Douketis
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Current Opinion in Hematology|August 12, 2005
Hormone replacement therapy and risk for venous thromboembolism: what's new and how do these findings influence clinical practice?James Douketis
ACP Journal Club|May 3, 2002
Review: stress hyperglycemia after ischemic stroke indicates a greater risk for death in patients without diabetesJames Douketis
Annals of Internal Medicine|May 18, 2011
ACP journal club. Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacementJames Douketis
ACP Journal Club|March 5, 2003
Heparin plus alteplase reduced morbidity more than heparin alone in submassive pulmonary embolismJames Douketis
Annals of Internal Medicine|May 18, 2011
ACP journal club. Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatmentJames Douketis
ACP Journal Club|September 5, 2002
Review: postmenopausal estrogen replacement therapy increases the risk for venous thromboembolismJames Douketis
Annals of Internal Medicine|July 22, 2009
ACP Journal Club. The devil is in the details...or not? A primer on individual patient data meta-analysisSachin Sud, James Douketis
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|April 29, 2014
New oral anticoagulants and oculoplastic surgeryEdsel Ing, James Douketis
Expert Opinion on Pharmacotherapy|February 19, 2013
Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient managementAaron Liew, James Douketis
BMJ (Clinical Research Ed.)|September 11, 2013
Secondary prevention of venous thromboembolismSam Schulman, James Douketis
Pageof 15